Drug Trial Radar · NCT00844597
Dose-Ranging Study of AVI-4658 to Induce Dystrophin Expression in Selected Duchenne Muscular Dystrophy (DMD) Patients
Last checked: Nov 20, 2026Latest source record: Oct 6, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
19
Actual
Start
Jan 2009
Primary completion
Jun 2010
Study completion Dec 2010
Sponsor
- Lead sponsor
- Sarepta Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- British Medical Research Council
- First posted
- Feb 16, 2009
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 5 years, up to 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The specific aim of this Phase I/II study is to assess the safety of intravenous administered Morpholino oligomer directed against exon 51 (AVI-4658 PMO).
Conditions
- Duchenne Muscular Dystrophy
Interventions
AVI-4658 for InjectionDrug
AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: Baseline to 6 months
- Treatment Emergent Adverse EventsTime frame: from Baseline to Follow up (27 weeks)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Great Ormond Street Hospital
London, England, United Kingdom
Royal Victoria Infirmary
Newcastle upon Tyne, England, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.